What is Affect?
Affect Therapeutics operates a digital health platform designed to address critical needs in substance use and mental health disorders. Delivered via smartphone, Affect's virtual clinic integrates multiple therapeutic modalities, including contingency management, structured counseling, medication management, and peer support. A key component is its AI-driven clinical decision support system, which facilitates real-time triage, crisis intervention, personalization, and provides deep clinician insights. The company partners with Medicaid, Medicare, and employer/commercial plans, aiming to make evidence-based care accessible, affordable, and scalable across diverse healthcare ecosystems.
How much funding has Affect raised?
Affect has raised a total of $50M across 3 funding rounds:
Seed
$1M
Series A
$23M
Series B
$26M
Seed (2021): $1M with participation from AlleyCorp companies
Series A (2023): $23M led by ARTIS Ventures
Series B (2025): $26M supported by ARTIS Ventures, City Light Capital, LifeArc Ventures, and Allumia Ventures
Key Investors in Affect
ARTIS Ventures
Artis Ventures is a venture capital fund specializing in Tech Bio+Health, backing innovative data-driven life sciences companies focused on enhancing human health. They invest in scalable medical technologies leveraging AI and engineering for personalized therapeutics and efficient drug discovery.
City Light Capital
City Light Capital is a venture capital firm that invests in early-stage companies, seeking both strong financial returns and positive societal contributions. They focus on Safety and Security, Education and Media, and Energy and Environment sectors.
AlleyCorp companies
AlleyCorp is an investment firm comprised of tech pioneers, investors, and entrepreneurs dedicated to building and investing in transformative businesses across various sectors, aiming to create impactful solutions for the present and future.
What's next for Affect?
The recent major strategic investment and the overall enterprise-level funding position Affect for significant expansion and market penetration. This capital infusion is expected to fuel further development of its AI capabilities, enhance its virtual clinic offerings, and broaden its reach within the payer and health system partnerships. As Affect continues to scale its operations, the company is poised to solidify its leadership in digital therapeutics for behavioral health, driving improved patient outcomes and cost efficiencies within the healthcare landscape.
See full Affect company page
